Interim committee reviews decades of North Dakota health‑insurance mandates and calls for clearer review processes

The North Dakota Legislative Interim Health Committee on Friday received a detailed review of the state's historical health‑insurance mandates and heard competing views on how mandates affect costs and access.

Legislative staff opened with a background memorandum summarizing statutory requirements for health‑insurance mandates, including the procedural framework under North Dakota Century Code section 54‑03‑28 and the PERS pilot period that temporarily applies new mandates to the state employee plan for evaluation before broader rollout. Staff listed statutes enacted from the 1980s through 2025 and highlighted how federal Affordable Care Act benchmark rules interact with state mandate obligations.

Why it matters: The committee is examining whether some mandates are outdated, whether the current process produces timely cost‑benefit information and whether the pilot and reporting timelines give lawmakers enough evidence before expanding mandates into the private market.

Blue Cross Blue Shield of North Dakota's Megan Ruby told the committee mandates can become misaligned with evolving medical evidence and technology, producing unintended costs. Ruby gave examples including statutory language on off‑label cancer drug use and prostate‑specific antigen screening, saying some mandates require coverage that no longer matches current guidance and that changes in drug development have altered expected costs. Ruby also explained the practical difference between fully insured plans (which state mandates can govern) and self‑funded employer plans (which generally are governed by federal ERISA rules), stressing that many constituents who ask for mandates are covered by plans to which state mandates do not automatically apply.

Sanford Health Plan's Dylan Wheeler urged procedural clarifications: he recommended a standing presumption that language such as "a health plan shall cover" trigger the formal mandate review process and cost‑benefit analysis, and suggested lengthening the period of pilot data collection (which often yields only 12–14 months of usable claims data) or expanding pilot populations to include Medicaid to improve the quality of evidence available to policymakers.

Rebecca Fricke, executive director of PERS, described the employee benefits committee role in vetting measures with fiscal impacts on the state plan, the April 1 interim submission timeline she favors for actuarial work, and the PERS pilot mechanics (measures effective July 1 and evaluated through the following June 30 so PERS can report utilization and cost). Fricke said the PERS reports are intended to give legislators actuarial and implementation detail before deciding whether to continue coverage beyond PERS membership.

Crystal Bartuska of the Insurance and Securities Department framed the issue under federal ACA rules: if a proposed benefit is outside the state's ACA benchmark, it can be treated as a new benefit that triggers a "state defrayal" requirement (the state would be responsible for paying the incremental cost to carriers for that benefit). She cited infertility coverage as a clear example of a benefit outside the benchmark that, if adopted, would require the state to defray costs to insurers under federal rules.

Public and provider perspectives varied. Representatives of carriers described voluntary programs that expand access without statutory mandates (examples included direct‑to‑member outreach for colorectal cancer screening and a Cologuard pilot), while health‑care providers, hospitals and a patient advocate from Susan G. Komen pressed for clearer rules and timely access to benefit and cost data. Bobby Will of Susan G. Komen said delays and procedural confusion have slowed wider commercial adoption of screening policies that first appeared in state employee plans.

Several legislators warned of operational friction when bills are dropped late in session and the committee is expected to act before analytic deadlines can be met. Multiple presenters and members suggested a standing schedule for periodic mandate review so statutes do not become permanently out of step with medical guidance.

The committee took no policy votes beyond adopting the meeting minutes; members directed staff and agencies to provide additional data, including more accessible cost‑benefit analyses and clarification on pharmacy network practices. The committee recessed for lunch and resumed with a separate dental study briefing later in the day.

Sources: presentations to the interim Health Committee, legislative background memorandum, testimony by Blue Cross Blue Shield of North Dakota, Sanford Health Plan, PERS, North Dakota Insurance Department and public commenters.

The committee will hold further interim work to refine deadlines, transparency measures for cost‑benefit analysis and options for periodic statutory review.